patent.fyi
Applications  /  US 2026/0355132
United States Patent Application Publication

US 2026/0355132 A1

Published
Nov 12, 2026
Filed
Aug 28, 2024
Earliest date on the face
Aug 29, 2023
Classification
A61K 31/137
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Epinephrine bitartrate in solution

What ifWhat if the formulation used epinephrine bitartrate as its epinephrine source?
Claim language“Epinephrine malonate salt”

The bitartrate salt dissolves in an acidic aqueous vehicle. The weighed salt mass accounts for the bitartrate counterion when setting the epinephrine concentration.

1.1Epinephrine free base feedstock

What ifWhat if the formulation process started with solid epinephrine free base?
Claim language“Epinephrine malonate salt”

The formulation process adds the weighed free base to an aqueous vehicle acidified with hydrochloric acid. Protonation of the amine increases aqueous solubility and produces dissolved epinephrine with chloride as the counterion.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

No entries.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 10,995,059 B2
Published
May 4, 2021
Filed
Jul 30, 2019
Class
C07C 215/60
Document BUS 2023/0086578 A1
Published
Mar 23, 2023
Filed
Nov 18, 2022
Class
C07C 215/60
Claim 1
Document A
Document B
1.1Epinephrine malonate salt as Form B.
An epinephrine malonate salt in crystalline form.
A · US 10,995,059 B2 · claim 1
In a preferred embodiment, the polymorphic crystalline epinephrine malonate has an x-ray powder diffraction pattern identified in FIG. 1.
B · US 2023/0086578 A1 · ¶ 4

An empty cell means only that no passage was reproduced there.

Statements in these documents
The pharmaceutical composition can be suitable for oral, rectal, intragastrical, topical, intracranial, intranasal, and parenteral administration.
A · US 10,995,059 B2 · ¶ 5
In certain embodiments, the pharmaceutical composition can disintegrate in less than or equal to 30 seconds.
A · US 10,995,059 B2 · ¶ 5
The pharmaceutical composition can be suitable for oral, rectal, intragastrical, topical, intracranial, intranasal, and parenteral administration.
B · US 2023/0086578 A1 · ¶ 5
In certain embodiments, the pharmaceutical composition can disintegrate in less than or equal to 30 seconds.
B · US 2023/0086578 A1 · ¶ 5
Cite aspatent.fyi, US 2026/0355132 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355132/, SHA-256 95e1a9d59fdf47e9879fce2fde947a2a59935282054e10d7f264e1294849e263
First published
Permanent addresshttps://patent.fyi/US20260355132/
Content fingerprint (SHA-256)95e1a9d59fdf47e9879fce2fde947a2a59935282054e10d7f264e1294849e263
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi